A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Denmark- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Denmark36 clinical trials in Gistrup, Denmark. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in DenmarkKliniske-Forsoeg.dk(opens in a new tab)
Denmark
Denmark
Denmark
Denmark
Denmark
Denmark
Denmark
Denmark
Denmark
Denmark
Denmark
DenmarkThe busiest research cities in the country
What the registry says about research in the country
Innovative research focusing on heart failure prevention through combination therapy studies. Clinical trials are evaluating the effectiveness of baxdrostat in combination with dapagliflozin for reducing cardiovascular mortality risk.
These studies aim to advance treatment options for patients at elevated risk of developing heart failure.
Groundbreaking research investigating chronic kidney disease management in patients with type 1 diabetes. Studies are examining the efficacy of finerenone as an addition to standard care treatment protocols.
This research focuses on developing enhanced therapeutic approaches for complex diabetic kidney complications.
Tell us about your condition – we search every trial in Europe and connect you with the right site.